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Abstract: Hyperhomocysteinemia is a factor that is found to be responsible for the development of atherosclerosis 
in the setting of chronic Helicobacter pylori (H. Pylori) infection. In the recent years, homocysteine (Hcy) has 
been demonstrated to be an important contributor to atherosclerosis. This study was undertaken to elucidate 
whether in patients with uremia on maintenance hemodialysis (HD), the infection of H. pylori affects the levels of 
Hcy. he patients were 39 HD ones with mean ages of 46±18 years. The time of   hemodialysis were 30± (35) 
months (median: 18 months). The value of serum Hcy of all patients was 5 (±2) µmol/L (median: 4.5 µmol/L). 
The value of serum H. Pylori specific IgG antibody titers was 7.6 (±9.9) u/ml (median: 2 u/ml). In this study a 
positive correlation was found between serum homocysteine and H. Pylori infection. As elevation of serum Hcy is 
observed in the great majority (>85%) of patients undergoing maintenance dialysis, further research is needed to 
determine the importance of association between elevated serum homocysteine and H. Pylori infection. 
Furthermore, whether or not the treatment of H. pylori infection in HD patients can diminish serum homocysteine 
level should be elucidated. 
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Introduction: 
Helicobacter pylori   (H. pylori) is a bacterium that 
causes infection in human stomach, and often leads 
to gastritis or peptic ulcer (1-3). Various data 
indicate a possible correlation between H. pylori 
infection and coronary heart disease (4-9). The link 
between H. pylori infection and 
hyperhomocysteinemia is a way to determine that 
this organism may be involved to the development 
of coronary diseases (10-13). Investigators have 
shown strong association between 
hyperhomocysteinemia and inadequate vitamin 
intake or insufficient vitamin concentrations in 
plasma, particularly vitamin B6, vitamin B12 and 
folate levels (14, 15). Several studies have shown 
that H. pylori infection has negative effects on 
serum vitamin B12 and folate levels (16-18). 
Metabolism of homocysteine (Hcy) involves a 
complex interaction between folate and vitamin 
B12 (19,22). It has been well established that 
chronic Helicobacter pylori infection causes 
gastritis (3,9,10) and decreased absorption of both 
folic acid  and vitamin B12 has been established in 
patients with this condition (19-22). This study was 
designed to examine whether in patients with 
uremia on maintenance HD, the infection of H. 
pylori affects the serum level of Hcy. 
 
Materials and Methods: 
This cross-sectional study was conducted on 
patients under routin hemodialysis. The etiologies 
of renal failure were diabetic nephropathy, 
hypertension, various glomerular diseases, 
autosomal dominant poly cystic kidney disease 
(ADPKD) and also urinary tract infections (23-35). 
According to the severity of secondary 
hyperparathyroidism, each patient was treated with 
oral active vitamin D3 (Rocaltrol), calcium 
carbonate, and Rena-Gel capsules at various doses. 
According to the severity of anemia, patients were 
treated with IV iron therapy Iron Source (venofer) 
at various doses after each dialysis session. All 
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patients were under treatment with 6 mg folic acid 
daily, oral vitamin B-complex tablet daily. Also, 
2000 U IV Eprex (recombinant human 
erythropoietin (rHuEPO) was given to each patient 
after each dialysis session routinely (35-37). All 
study patients had various upper gastrointestinal 
complaints consisting of epigastric pain, epigastric 
burning, post prandial fullness, early satiety, 
bloating and belching. Exclusion criteria for 
patients were using of proton pump inhibitors and 
antibiotics or taking aluminum hydroxide jells or 
having any active or chronic infection before the 
study. After an overnight fast, blood samples were 
collected. Serum homocysteine (total) was 
measured by enzyme-linked immunosorbent assay 
(ELISA) method using DRG kits (DRG 
Diagnostics, Berlin,Germany). Serum total 
Homocysteine (Hcy) has a normal range of 25-125 
µmol/L. Serum H.pylori specific IgG antibody titer 
(titer >10 U/mL was interpreted as positive 
according to the kit) was measured by ELISA 
method using Trinity Biotech Kits (USA). For the 
efficacy (adequacy) of hemodialysis the urea 
reduction rate (URR) was calculated from pre-and 
post blood urea nitrogen (BUN) data (38). Body 
mass index (BMI) was calculated using the 
standard formula (post dialyzed weight in 
kilograms/height in square meters; kg/m²) (39). 
Duration and amount of hemodialysis were 
calculated from patients' records. The duration of 
each hemodialysis session was four hours. For 
statistical analysis, the data are expressed as the 
Mean ± SD and madian values. For correlations we 
used partial correlation test. For comparison 
between groups, student's t-test was used. All 
statistical analyzes were performed using SPSS 
(version 11.5.00). Statistical significance was 
determined at a p-value lower than 0.05. 
 
Results: 
    The study was conducted on 39 (female=15, 
male=24) maintenance HD patients. Of 39 patients, 
12 were diabetic. Mean age of patients was 46 
(±18) years. The duration the patients were on HD 
was 30± (35) months (median: 18 months). The 
value of serum Hcy of patients was 5 (±2) µmol/L 
(median: 4.5µmol/L). Mean±SD of hemoglobin and 
hematocrit levels of all patients were 9±2 g/dL 
(median: 9 g/dL), and 28±6% (median: 29%), 
respectively. The value of serum H. pylori IgG 
antibody titer was 7.6 (±9.9) U/mL (median: 2 
U/mL). Serum H. pylori antibody titer in the female 
and male groups were 5.9 (±8) U/mL (median: 2 
u/ml) and 8.7 (±10.9) U/mL (median: 2 U/mL), 
respectively. In this study no significant difference 
of serum homocysteine and H. pylori  IgG antibody 
level between male and female group or diabetic 
and non-diabetic HD patients were found (p>0.05). 
In non- diabetic group, a significant positive 
correlation between serum Hcy and anti H. pylori 
antibody level (r= 0.77, p=0.016) was found. Also, 
in male group also a significant positive correlation 
between serum Hcy and anti H. pylori antibody (r= 
0.56, p =0.028) (adjusted for age and duration and 
amount of dialysis) was seen. No significant 
correlation between serum Hcy and H. pylori - IgG 
antibody in all patients, female group or diabetic 
HD groups was seen (p>0.05). 
 
Discussion: 
Uremia represent is associated with 
hyperhomocysteinemia (40-42). Hcy is a sulphur 
amino acid drived from methionine during 
transmethylation, and is either salvaged to 
methionine by a folate and cobalamin dependent 
remethylation reaction or directed toward 
degradation by the vitamin B6-dependent enzyme 
cystathionine β-synthase (41-43). Various studies 
have shown that moderate hyperhomocysteinemia 
is an independent risk factor for premature 
atherosclerosis and cardiovascular disease (40-43). 
Mild-to-moderate elevations in serum 
homocysteine levels are observed in the great 
majority (>85%) of patients with end-stage renal 
disease who are undergoing maintenance dialysis 
(43-46). Deficiency of vitamin B12 raises the 
serum and tissue levels of Hcy (47,48). Atrophic 
corpus gastritis results in impaired secretion of 
intrinsic factor and may lead to malabsorption of 
vitamin B12 in the intestine (49,50). In a study 
conducted by Aguilera et al. on 1313 peritoneal 
dialysis patients showed that infection with H. 
pylori was associated with anorexia, inflammation, 
and malnutrition in their patients (48). Eradication 
of H. pylori significantly improves this syndrome 
(49, 50). In our previous studies association of H. 
pylori infection with serum albumin and other 
nutritional parameters were shown (1, 2). To test 
the hypothesis that, chronic gastritis induced by 
Helicobacter pylori causes malabsorption of 
vitamin B12 and folate  and  lead to an increase in 
circulating Hcy level, Tamura et al. conducted a 
study on 93 patients who underwent diagnostic 
coronary arteriography (51). Study patients were 
divided into two groups according to the presence 
or absence of H. pylori infection. The study 
suggests that H. pylori - induced chronic gastritis 
decreases plasma vitamin B12 and folic acid levels, 
thereby increasing Hcy levels (51). In the study 
carried out by Sipponen et al. a low serum level of 
vitamin B12 that was associated with atrophic 
corpus gastritis in a sample of 12.252 men (age 51-
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65 years) from two cites in Finland was found (47). 
Of these men, 72% (128 of 179 tested) had elevated 
Helicobacter pylori antibody levels. They 
concluded that low serum levels of vitamin B12 
related to atrophic corpus gastritis is relatively 
common (prevalence 2.5%) among elderly male 
patients in the general population (47). To find, 
whether serum vitamin B12 levels in non-vitamin 
B12 deficient healthy adults correlate with 
serological evidence of H. pylori infection, Shuval-
Sudai et al. studied 133 adults with a history of H. 
pylori eradication. They found that the higher 
prevalence of H. pylori infection among 
participants with serum vitamin B12 level within 
the lower end of the normal range, suggests a 
causal relationship between H. pylori infection and 
vitamin B12 levels in healthy adults (52). Hence, 
there is an association between Helicobacter pylori 
infection, reduced cobalamin absorption and 
cobalamin status. Consequently, elevated 
homocysteine levels, could offer an explanation 
why H. pylori infection is associated with coronary 
heart disease (53-67). However, in a meta-analysis 
study, testing10.000 patients, revealed no 
meaningful correlations between H. pylori and 
vascular risk factors (68). It is possible that 
homocysteine can directly cause endothelial 
damage (69-75), affect platelet function and 
coagulation factors (69), and increase the oxidation 
of low-density lipoproteins (76). Indeed in the light 
of these findings, a number of studies have focused 
on H. pylori infection as a possible cause of 
hyperhomocysteinemia in the general population. 
However, in HD patients other factors are also 
responsible for high serum levels of homocysteine 
(41,77). As noted above, in the present study we 
found a significant positive correlation betwee 
serum homocysteine and H. pylori infection. It has 
been well established that chronic H. pylori 
infection causes atrophic gastritis (1-5), and 
decreased absorption of both vitamin B12 and folic 
acid has been documented in patients with this 
condition (1-5). Patients with chronic H. pylori 
infection exhibited decreased secretion of ascorbic 
acid by the gastric mucosa and elevated gastric pH 
(78,79). It has been demonstrated that low levels of 
ascorbic acid in gastric juice or high pH of gastric 
juice could cause less folate absorption from the 
diet (80,81). Even in dyspeptic H. pylori - positive 
patients who do not exhibit gastric mucosal 
atrophy, complete eradication of H. pylori is 
associated with a significant drop in serum Hcy 
(65). Taken together, hyperhomocysteinemia is a 
factor that is suggested to be responsible for the 
development of atherosclerosis in the setting of 
chronic H. pylori infection (80,81). Homocysteine 
has been shown to be an important contributor to 
atherosclerosis as mentioned. Since in HD patients 
we also have hypermomocysteinemia,more 
researches are needed to determine the importance 
of this association in HD  patients and whether or 
not treatment of H. pylori infection in hemodialysis 
patients can diminish serum homocysteine level. 
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